RT Journal Article
SR Electronic
T1 The impact of supervised beego, a traditional Chinese water-only fasting, on thrombosis and hemostasis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.31.20166215
DO 10.1101/2020.07.31.20166215
A1 Yixuan Fang
A1 Yue Gu
A1 Chen Zhao
A1 Yaqi Lv
A1 Jiawei Qian
A1 Lingjiang Zhu
A1 Na Yuan
A1 Suping Zhang
A1 Li Wang
A1 Mengli Li
A1 Qing Zhang
A1 Li Xu
A1 Wen Wei
A1 Lei Li
A1 Li Ji
A1 Xueqin Gao
A1 Jingyi Zhang
A1 Yueping Shen
A1 Zixing Chen
A1 Guanghui Wang
A1 Kesheng Dai
A1 Jianrong Wang
YR 2020
UL http://medrxiv.org/content/early/2020/12/10/2020.07.31.20166215.abstract
AB Beego is a traditional Chinese complete water-only fasting practice initially developed for spiritual purposes, later extending to physical fitness purposes. Beego notably includes a psychological induction component that includes meditation and abdominal breathing, light body exercise, and ends with a specific gradual refeeding program before returning to a normal diet. Beego has regained its popularity in recent decades in China as a strategy for helping people in subhealthy conditions or with metabolic syndrome, but we are unaware of any studies examining the biological effects of this practice. To address this, we here performed a longitudinal study of beego comprising fasting (7 and 14 day cohorts) and a 7-day programmed refeeding phase. In addition to detecting improvements in cardiovascular physiology and selective reduction of blood pressure in hypertensive subjects, we observed that beego decreased blood triacylglycerol (TG) selectively in TG-high subjects and increased cholesterol in all subjects during fasting; however, the cholesterol levels were normalized after completion of the refeeding program. Strikingly, beego reduced platelet formation, activation, aggregation, and degranulation, resulting in an alleviated thrombosis risk, yet maintained hemostasis by sustaining levels of coagulation factors and other hemostatic proteins. Mechanistically, we speculate that downregulation of G6B and MYL9 may influence the observed beego-mediated reduction in platelets. Fundamentally, our study supports that supervised beego reduces thrombosis risk without compromising hemostasis capacity. Moreover, our results support that beego under medical supervision can be implemented as noninvasive intervention for reducing thrombosis risk, and suggest several lines of intriguing inquiry for future studies about this fasting practice (http://www.chictr.org.cn/index.aspx, number,ChiCTR1900027451).Competing Interest StatementThe authors have declared no competing interest.Clinical Trialhttp://www.chictr.org.cn/index.aspx, number, ChiCTR1900027451Funding StatementThis study was supported by the National Natural Science Foundation of China (to JW) by grants 91649113 and 31771640, and by Soochow University (to JW) by grant H190443, and by the Natural Science Foundation of Jiangsu Province, China (to YF) by grant SBK2020043689, and by The Postdoctor Science Foundation of Jiangsu Province (to YF) by grant 2020Z064, and by the Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Province, China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval No. ECSU-2019000153 by Ethics Review Board at Soochow University, ChinaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors upon request.AIxaugmentation indexAPTTactivated partial thromboplastin timeAT IIIantithrombin III testingBDNFbrain-derived neurotrophic factorCNScentral nervous systemCOGscluster of orthologous groupsDBPdiastolic blood pressureDDAdata-dependent acquisitionDIAdata-independent acquisitionDTTdithiothreitolELISAEnzyme-linked immunosorbent assayFIBFibrinogenFITCfluoresceine isothiocyanateGOGene ontologyHDL-Chigh-density lipoprotein cholesterolINRinternational normalized ratioLC-MS/MSliquid phase chromatographyLDL-Clow-density lipoprotein cholesterolMPVMean platelet volumePCTplatelet hematocritPDWplatelet distribution widthPEphycoerythrinPLTplateletPPIprotein-protein interactionPRPplatelet-rich plasmaPTprothrombin timePWApulse wavePWVpulse wave velocityrFDrefeeding daysRMrepeated measuresROSreactive oxygen speciesRTroom temperatureSBPsystolic blood pressureSEMstandard error of the meanSOPstandard operating proceduresSPEsolid phase extractionTCtotal cholesterolTGtriacylglycerolTPOthrombopoietinTTthrombin timewFDwater-only fasting day.